Skip to main content

04-06-2021 | EULAR 2021 | Conference coverage | Video

Risankizumab shows promise for PsA in the KEEPsAKE 2 trial

Andrew Östör talks about the results of KEEPsAKE 2, a phase 3 trial of risankizumab versus placebo in patients with psoriatic arthritis, and explores how the IL-23 inhibitor may impact clinical practice if approved by the regulatory authorities (3:39).

Read transcript

EULAR 2021 Virtual Congress coverage

Access news and expert commentary from the EULAR 2021 Virtual Congress.

Image Credits